0001354457-24-000196.txt : 20240321
0001354457-24-000196.hdr.sgml : 20240321
20240321142325
ACCESSION NUMBER: 0001354457-24-000196
CONFORMED SUBMISSION TYPE: 25-NSE
CONFIRMING COPY:
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20240321
DATE AS OF CHANGE: 20240321
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: INVIVO THERAPEUTICS HOLDINGS CORP.
CENTRAL INDEX KEY: 0001292519
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 000000000
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-52089
BUSINESS ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BUILDING 1400 EAST 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-863-5524
MAIL ADDRESS:
STREET 1: ONE KENDALL SQUARE
STREET 2: BUILDING 1400 EAST 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Design Source, Inc.
DATE OF NAME CHANGE: 20040602
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: Nasdaq Stock Market LLC
CENTRAL INDEX KEY: 0001354457
ORGANIZATION NAME:
IRS NUMBER: 521165937
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: One Liberty Plaza
CITY: New York
STATE: NY
ZIP: 10006
BUSINESS PHONE: 301-978-4144
MAIL ADDRESS:
STREET 1: Office of General Counsel
STREET 2: 805 King Farm Blvd.
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: The Nasdaq Stock Market LLC
DATE OF NAME CHANGE: 20060224
25-NSE
1
primary_doc.xml
X0203
0001354457
Nasdaq Stock Market LLC
0001292519
INVIVO THERAPEUTICS HOLDINGS CORP.
000-52089
One Kendall Square, Suite B14402
Cambridge
MA
MASSACHUSETTS
02139
(617) 863-5524
Common stock
17 CFR 240.12d2-2(b)
Aravind Menon
Hearings Advisor
2024-03-20
EX-99.25
2
nvivdelistreason.txt
Delisting Determination, The Nasdaq Stock Market, LLC, March 21, 2024,
InVivo Therapeutics Holdings Corp.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the securities of InVivo Therapeutics Holdings Corp.,
effective at the opening of the trading session on April 1, 2024.
Based on review of information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for listing on the
Exchange pursuant to Listing Rules 5101, 5110(b), and IM-5101-1.
The Company was notified of the Staff determination on February 2,
2024. The Company did not appeal the Staff determination to the
Hearings Panel. The Company securities were suspended on February 13,
2024. The Staff determination to delist the Company securities
became final on February 13, 2024.